Jingsong Wang – Founder, Chairman & CEO, Harbour BioMed
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases. The company’s discovery and development programs are centered around its two patented transgenic mouse platforms generating fully human monoclonal antibodies.
The company is building its proprietary pipeline internally, through collaborations with co-development partners, as well as through select preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary.
Harbour BioMed has operation and an R&D site in Shanghai, China, business operations and innovation center including research laboratory in Boston, USA, and an antibody platform innovation center in Rotterdam, The Netherlands.
Contact
Suite 311, 866 Halei Road, Pudong New Area, Shanghai, China
Tel: +86 21 51370990
Website: http://www.harbourbiomed.com
Email: contact@harbourbiomed.com
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since…
Harbour BioMed is a fast-growing global biotech company with facilities in Rotterdam, Boston and Shanghai. The company is laser-focused on developing both proprietary and in-licensed immunological therapies using their state-of-the-art…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for…
Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He…
Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its…
From factory automation in Silicon Valley to scalable service robotics embedded in daily care, Roy Long Hei’s journey with Robocore reflects a disciplined belief that technology must prove itself in…
Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute…
China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy…
Cancer drug development has produced an abundance of therapies, yet outcomes in solid tumours remain constrained by resistance and relapse. In this interview, Zaiqi Wang, Chairman and CEO of InxMed,…
Shaped by decades across US biotech, big pharma, and China’s high-intensity innovation environment, Dr Jing Li brings a rare end-to-end perspective on how biologics move from idea to impact. In…
See our Cookie Privacy Policy Here
